8-KLeadership ChangesExhibits & Filings

BRISTOL MYERS SQUIBB CO 8-K Report, Executive Changes (Jan 31, 2023)

Filed January 31, 2023For Securities:BMYCELG-RIBMYMP

Summary

Bristol Myers Squibb Company (BMY) has filed an 8-K report on January 30, 2023, announcing the departure of Dr. Rupert Vessey, Executive Vice President of Research and Early Development, effective July 3, 2023. This executive transition marks a notable change in the company's research leadership. While Dr. Vessey's departure is confirmed, the company has outlined the financial and equity arrangements associated with his exit. Investors should note the specific details regarding Dr. Vessey's severance benefits, which will be in line with the company's Senior Executive Severance Plan. Additionally, his equity awards, including Market Share Units (MSUs) and Performance Share Units (PSUs), will vest on a pro-rated basis. Notably, his 2019 Restricted Stock Units Inducement Award will vest in full. He will also receive a pro-rated annual incentive payout for 2023. These details provide transparency on the financial implications of this executive departure.

Key Highlights

  • 1Dr. Rupert Vessey, EVP of Research and Early Development, is departing Bristol Myers Squibb.
  • 2The departure is effective July 3, 2023.
  • 3Dr. Vessey will receive severance benefits under the company's Senior Executive Severance Plan.
  • 4Certain equity awards, including MSUs and PSUs, will have pro-rated vesting.
  • 5Dr. Vessey's 2019 Restricted Stock Units Inducement Award will vest in full.
  • 6A pro-rated annual incentive payout of $550,855 for 2023 will be provided to Dr. Vessey.

Frequently Asked Questions

Dr. Rupert Vessey holds a key leadership position as Executive Vice President of Research and Early Development. His departure signifies a change in the company's top research leadership, which could have implications for the direction and progress of BMY's research and development pipeline.

Investors should note that Dr. Vessey will receive severance benefits, pro-rated vesting of certain equity awards (MSUs and PSUs), full vesting of his 2019 Restricted Stock Units Inducement Award, and a pro-rated annual incentive payout of $550,855 for 2023. These payments are part of standard executive departure arrangements.

The immediate impact on ongoing research projects is not detailed in this filing. However, executive transitions in R&D leadership can sometimes lead to shifts in strategic priorities or project focus over time. Investors will likely monitor future communications for any indications of changes in R&D strategy.

This 8-K filing does not specify any non-compete clauses or restrictions. Such details, if any, are typically part of separate agreements not disclosed in this report.